A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
Anticancer Res
; 36(3): 957-65, 2016 Mar.
Article
in En
| MEDLINE
| ID: mdl-26976984
ABSTRACT
BACKGROUND/AIM:
To assess preoperative blood levels of a biomarker panel in relation to the new classification system of epithelial ovarian cancer (EOC) type I and II. PATIENTS ANDMETHODS:
Preoperative plasma levels of B7-family protein homolog 4 (B7-H4), intact and cleaved soluble urokinase plasminogen activator receptor (suPAR), human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) were analyzed in 350 patients with adnexal lesions.RESULTS:
The levels of suPAR(II-III), HE4, CA125 were all higher in EOC II than in EOC I, borderline and benign ovarian tumors. B7-H4 was increased in EOC II compared with benign ovarian tumors. The combination of suPAR(II-III), HE4, CA125 and age in premenopausal women discriminates EOC and borderline tumors from benign tumors to higher accuracy compared to the Risk of Ovarian Malignancy Algorithm (p=0.007).CONCLUSION:
The biomarker panel suPAR(II-III), HE4, CA125 and age in premenopausal women improved discrimination of malignant and benign ovarian tumors. The plasma levels of B7-H4 were increased in patients with EOC II compared to those with benign ovarian tumors.Key words
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Urokinase-Type Plasminogen Activator
/
Proteins
/
Biomarkers, Tumor
/
Neoplasms, Glandular and Epithelial
/
CA-125 Antigen
/
V-Set Domain-Containing T-Cell Activation Inhibitor 1
/
Membrane Proteins
Type of study:
Diagnostic_studies
/
Screening_studies
Limits:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Anticancer Res
Year:
2016
Document type:
Article